AccessMyLibrary provides FREE access to over 30 million articles from top publications available through your library.
Create a link to this page
Copy and paste this link tag into your Web page or blog:
2004 SEP 1 - (NewsRx.com & NewsRx.net) -- Investigators compare antigen-loading strategies of dendritic cells for tumor immunotherapy in a recent issue of the Journal of Immunotherapy.
"Dendritic cells (DCs) loaded with antigens can effectively stimulate host immune responses to syngeneic tumors, but there is considerable controversy as to which forms of antigen-loading are most immunogenic. Here, the authors compared immunotherapeutic reactivities of DCs loaded with a variety of antigen preparations. Because DC maturation stages affect their capacities of antigen processing and presentation, two DC populations were used for the current analysis: in vivo Flt-3 ligand-induced mature DCs and in vitro bone marrow-derived DCs, which were less mature," researchers in the United States report.
"To facilitate a direct comparison, the LacZ gene-transduced B16 melanoma model system was used, where beta-galactosidase served as the surrogate tumor-rejection antigen," said Kenji Shimizu and colleagues at the Cleveland Clinic. "DC loading strategies included pulsing with the beta-galactosidase protein, H-2K[superscript]b restricted peptide, tumor cell lysate, and irradiated tumor cells and fusion of DCs with tumor cells. Our results demonstrated that electrofusion of DCs and tumor cells generated a therapeutic vaccine far superior to other methods of DC loading."
"For the treatment of 3-day established pulmonary tumor nodules, a single intranodal vaccination ...
Source: HighBeam Research, Antigen-loading strategies of dendritic cells for cancer vaccines...